Development and characterization of a preclinical model of breast cancer lung micrometastatic to精选.pdfVIP

Development and Characterization of a Preclinical Model of Breast Cancer Lung Micrometastatic to Macrometastatic Progression 1. 1,2. 1 2 1,3 Lora C. Bailey-Downs , Jessica E. Thorpe , Bryan C. Disch , Anja Bastian , Paul J. Hauser , 1 4 1,3,5 1,2 Taleah Farasyn , William L. Berry , Robert E. Hurst , Michael A. Ihnat * 1 DormaTarg, Inc., Oklahoma City, Oklahoma, United States of America, 2 Department of Pharmaceutical Sciences, University of Oklahoma College of Pharmacy, Oklahoma City, Oklahoma, United States of America, 3 Department of Urology, University of Oklahoma College of Medicine, Oklahoma City, Oklahoma, United States of America, 4 Department of Cell Biology, University of Oklahoma College of Medicine, Oklahoma City, Oklahoma, United States of America, 5 Department of Biochemistry and Molecular Biology, of Oklahoma College of Medicine, Oklahoma City, Oklahoma, United States of America Abstract Most cancer patients die with metastatic disease, thus, good models that recapitulate the natural process of metastasis including a dormancy period with micrometastatic cells would be beneficial in developing treatment strategies. Herein we report a model of natural metastasis that balances time to complete experiments with a reasonable dormancy period, which can be used to better study metastatic progression. The basis for the model is a 4T1 triple negative syngeneic breast cancer model without resection of the primary tumor. A cell titration from 500 to 15,000 GFP tagged 4T1 cells implanted into fat pad number four of immune proficient